公开(公告)号：US12122831B2

公开(公告)日：2024-10-22

申请号：US17072842

申请日：2020-10-16

Applicant: Lentigen Technology, Inc.

Inventor： Dina Schneider ,  Rimas J. Orentas ,  Boro Dropulic ,  Peirong Hu

IPC: C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725

CPC classification number: C07K16/2803 ,  A61K35/17 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  A61K38/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

公开(公告)号：US12116417B2

公开(公告)日：2024-10-15

申请号：US16764276

申请日：2018-11-14

Applicant: GC CELL CORPORATION

Inventor： Jong Seo Lee ,  Kyu Tae Kim ,  Young Ha Lee ,  In Sik Hwang ,  Bong Kook Ko

IPC: C07K16/32 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  G01N33/574

CPC classification number: C07K16/32 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  G01N33/574 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds. When compared with trastuzumab, the antibody of the present disclosure exhibits better killing ability for HER2-unexpressed cancer cells which have non-reactivity (or resistance) to the trastuzumab antibody or have reduced sensitivity. In addition, when the anti-HER2 antibody of the present disclosure is administered in combination with trastuzumab, a synergistic killing ability is achieved for cancer cells on which the trastuzumab antibody acts. Therefore, a composition of the present disclosure can be very usefully used for combined administration with the trastuzumab antibody for the treatment of cancer, or for the treatment of cancer not treated with trastuzumab.

公开(公告)号：US12115214B2

公开(公告)日：2024-10-15

申请号：US16685424

申请日：2019-11-15

Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V

Inventor： Rikard Holmdahl ,  Jan Kihlberg ,  Balik Dzhambazov ,  Mikael Vestberg

IPC: A61K39/00 ,  A61K47/64 ,  A61K47/68 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18

CPC classification number: A61K39/0008 ,  A61K47/6425 ,  A61K47/6811 ,  A61K47/6843 ,  C07K7/08 ,  C07K14/4713 ,  C07K14/705 ,  C07K16/18 ,  A61K2039/605 ,  A61K2039/6056 ,  C07K2319/33

Abstract: The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated.

公开(公告)号：US20240336680A1

公开(公告)日：2024-10-10

申请号：US18753205

申请日：2024-06-25

Applicant: ACCURUS BIOSCIENCES, INC.

Inventor： Haishan Lin ,  Richard Zhang

IPC: C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  C07K14/725 ,  G01N33/68

CPC classification number: C07K16/28 ,  A61K47/6849 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  G01N33/6854 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Provided herein are novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-CLDN 18.2 CAR, anti-CLDN18.2 antibody-drug conjugates (ADCs), bispecific antibodies containing anti-CLDN 18.2 antibody, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-CLDN 18.2 antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting CLDN 18.2.

公开(公告)号：US20240335475A1

公开(公告)日：2024-10-10

申请号：US18749513

申请日：2024-06-20

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

Inventor： Renier J. Brentjens ,  Eric L. Smith ,  Cheng Liu

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2878 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2740/10043 ,  C12N2840/203

Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BCMA), and immunoresponsive cells comprising such CARs. The presently disclosed BCMA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

公开(公告)号：US12111319B2

公开(公告)日：2024-10-08

申请号：US17385834

申请日：2021-07-26

Applicant: HESPERIX SA ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Alexey Vyacheslavovich Stepanov ,  Dmitry Dmitrievich Genkin ,  Alexander Gabibovich Gabibov ,  Richard A. Lerner ,  Alexey Anatolievich Belogurov ,  Jia Xie

IPC: G01N33/574 ,  A61K35/17 ,  A61K39/00 ,  C07K16/28 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/543

CPC classification number: G01N33/57492 ,  A61K35/17 ,  A61K39/0011 ,  C07K16/2803 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/543 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/54 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/73 ,  C07K2319/03 ,  C07K2319/33 ,  C12Q2600/156

Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.

公开(公告)号：US12104178B2

公开(公告)日：2024-10-01

申请号：US17646212

申请日：2021-12-28

Applicant: Obsidian Therapeutics, Inc.

Inventor： Vipin Suri ,  Dan Jun Li ,  Dexue Sun ,  Byron Delabarre ,  Vijaya Balakrishnan ,  Brian Dolinski ,  Mara Christine Inniss ,  Grace Y. Olinger

IPC: A61K35/17 ,  C07K14/54 ,  C07K14/705 ,  C07K14/715 ,  C12N9/06 ,  C12N15/85 ,  C12N15/86

CPC classification number: C12N9/003 ,  A61K35/17 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/70503 ,  C07K14/7155 ,  C12N15/85 ,  C12Y105/01003 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present invention is related to compositions and methods for the regulated and controlled expression of proteins.

公开(公告)号：US20240317835A1

公开(公告)日：2024-09-26

申请号：US18733576

申请日：2024-06-04

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Andrew Tustian ,  Ankit Vartak ,  Thomas Daly ,  Erica Pyles ,  Nisha Palackal ,  Shunhai Wang ,  Ning Li

IPC: C07K14/71 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/02 ,  G01N30/80

CPC classification number: C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

公开(公告)号：US20240294665A1

公开(公告)日：2024-09-05

申请号：US18663557

申请日：2024-05-14

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic

Inventor： Qiong J. Wang ,  Zhiya Yu ,  James C. Yang

IPC: C07K16/30 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28

CPC classification number: C07K16/30 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/7153 ,  C07K16/2875 ,  A61K35/17 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33

Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3ζ intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

公开(公告)号：US12077598B2

公开(公告)日：2024-09-03

申请号：US16978945

申请日：2019-03-15

Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.

Inventor： Daniel Abate-Daga ,  Cecilia Ramello

IPC: C07K16/30 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: C07K16/30 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a costimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 with altered phosphorylation at Y206 and/or Y218. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an antitumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.